Johnson & Johnson, Janssen Biotech Facing Another Class Action Over Remicade ‘Scheme’
December 14, 2017 J&J and Janssen Biotech face more allegations the companies operated an 'exclusionary, competition-killing scheme' to maintain market control.
Lawsuit Filings
J&J, Janssen Biotech Pegged with Antitrust Lawsuit Over Pricing of Blockbuster Drug Remicade
November 15, 2017 An antitrust lawsuit alleges Johnson & Johnson and Janssen Biotech rigged the pricing for Remicade, a 'blockbuster' drug used to treat Crohn's Disease.
Johnson & Johnson Faces Antitrust Suit Over Dominating Infliximab Drug
October 6, 2017 Johnson & Johnson (J&J) and subsidiary Janssen Biotech, Inc. are facing a lawsuit alleging they engaged in an illegal antitrust scheme to raise prices of their infliximab drug and suppress competition.